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Parkinson’s disease (PD) represents a major challenge for health care systems around the world: 
it is the most common degenerative movement disorder of old age, affecting over 100,000 
people in the UK alone (Schrag et al., 2000). Despite the remarkable success of treatments 
directed at potentiating or replacing dopamine within the brain, which can relieve symptoms 
for over a decade, PD remains an incurable and invariably fatal disorder. As such, efforts to 
understand the processes that lead to cell death in the brains of patients with PD are a priority 
for neurodegenerative researchers. A great deal of progress has been made in this regard by 
taking advantage of advances in genetics, initially by the identification of genes responsible for 
rare Mendelian forms of PD (outlined in Table 1), and more recently by applying genome wide 
association studies (GWAS) to the sporadic form of the disease (Hardy et al., 2009). Several 
such GWAS have now been carried out, with a meta-analysis currently under way. Using over 
6000 cases and 10,000 controls, two of these studies have identified variation at a number of 
loci as being associated with an increased risk of disease (Satake et al., 2009; Simon-Sanchez 
et al., 2009).  Three genes stand out as candidates from these studies – the SNCA gene, coding 
for α-synuclein, the LRRK2 gene, coding for leucine rich repeat kinase 2, and MAPT, coding for 
the microtubule-associated protein tau. Mutations at all three of these loci have been associated 
with Mendelian forms of disease presenting with the clinical syndrome of Parkinsonism, 
however only SNCA and LRRK2 have been previously associated with pathologically defined 
PD (Hardy et al., 2009). Point mutations in α-synuclein, along with gene multiplication events, 
result in autosomal dominant PD, often with a significant dementia component. In addition to 
this, α-synuclein is the principle component of the main pathological hallmark of idiopathic PD, 
the Lewy body, making it an unsurprising hit in the GWAS (Spillantini et al., 1997). Mutations 
in LRRK2 are the most common genetic cause of PD, and so again made this gene a likely 
candidate as a susceptibility locus for the sporadic form of disease (Kumari and Tan, 2009). 
More surprising, perhaps, was the identification of tau as a susceptibility factor for Parkinson’s. 
In this review we will outline the role of tau in neurodegeneration and in different forms of 
Parkinsonism, and speculate as to what the functional basis of the association between MAPT 
and PD might be.
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(Grundke-Iqbal et al., 1986). The discovery of familial AD   mutations 
that increase Aβ production led to the development of the amy-
loid cascade hypothesis, where tau pathology sits downstream of 
Aβ in the pathological cascade (Hardy and Allsop, 1991; Hardy 
and Higgins, 1992). For many years afterward, there was debate 
as to whether tau pathology was critical for disease pathogenesis, 
or was just a non-specific marker of disease. Several studies have 
shown that tau is necessary for Aβ-mediated toxicity, for example 
primary neuronal cultures from tau knockout mice are resistant 
to Aβ, and crossing APP transgenic mice with tau knockout mice 
resulted in a reduction of Aβ induced deficits (Rapoport et al., 2002; 
Roberson et al., 2007). The presence of NFTs correlates highly with 
the degree of dementia in AD suggesting a central role for tau in 
neuronal demise (Braak and Braak, 1991). This, combined with 
the discovery of mutations in the tau gene (MAPT) that cause 
frontotemporal dementia (discussed further below), have made 
understanding the links between tau and neuronal death an area 
of intense research.
Tau proTein and iTs role in neurodegeneraTion
The microtubule-associated protein tau is a predominantly neuro-
nal protein whose major function is to bind to and stabilize micro-
tubules. In the adult human CNS, tau exists as six protein isoforms 
which differ by the presence of either 0, 1, or 2 N-terminal inserts 
and either three (3R) or four (4R) microtubule binding repeats 
located at the C terminus of the protein (Goedert et al., 1989; 
Andreadis et al., 1992). Tau binds to and stabilizes microtubules 
via its C-terminal repeats in a process regulated by phosphoryla-
tion, where the phosphorylation of tau at specific residues favors 
its detachment from the microtubules (Lindwall and Cole, 1984).
In neurodegenerative disease, hyperphosphorylated, insoluble 
aggregates of tau are observed in neurons and glia of affected brain 
regions. Such disorders are collectively named the tauopathies, 
the most well known of which is Alzheimer’s disease (AD), where 
neurofibrillary tangles (NFTs) comprised of hyperphosphorylated, 
insoluble tau are one of the defining pathological features of the 
disease, alongside extracellular plaques composed of Aβ peptide Frontiers in Psychiatry  |  Neurodegenerative Diseases    December 2010  | Volume 1  | Article 150  |  2
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located within the largest known block of linkage disequilibrium in 
the human genome, spanning 1.8 Mb, where the two major haplo-
types are termed H1 and H2 (Stefansson et al., 2005). Homozygosity 
for the H1 haplotype has been shown to be strongly associated 
with increased risk of developing PSP and CBD in several popula-
tions (Conrad et al., 1997; Baker et al., 1999; Houlden et al., 2001; 
Pittman et al., 2004, 2006). Further dissection of the MAPT locus 
has revealed H2 to be largely invariant, whereas H1 can be divided 
into the subhaplotypes H1a, H1b, and H1c (Pittman et al., 2004, 
2006). Of these, it is the H1c haplotype which exhibits the strongest 
association with PSP and CBD (Pittman et al., 2004, 2006).
The strongest association of the H1 haplotype with PSP and 
CBD has been mapped to the promoter region of MAPT (Myers 
et al., 2007), and as both the H1 and H2 haplotypes produce tau 
protein with the same coding sequence, it is logical to hypothesize 
that they may influence disease risk by altering expression levels 
or splicing of tau. This concept, where increased levels of normal 
sequence proteins are sufficient to cause neurodegeneration, has 
been described previously, for example duplications and triplica-
tions of SNCA cause PD, and AD-type pathology is seen in Down’s 
syndrome where triplication of the APP gene occurs (Hardy, 2005). 
Tau levels, in particular the 4R isoforms, were found to be higher 
in post-mortem tissue from H1 homozygotes than H1/H2 hetero-
zygotes and H2 homozygotes (Myers et al., 2007). In vitro reporter 
assays have shown the H1 promoter region to exhibit increased 
transcriptional activity when compared to H2 and allele-specific 
expression  assays  in  H1/H2  heterozygote  neuroblastoma  have 
shown that 4R tau isoform production is highest from the H1 allele 
(Caffrey et al., 2006). These experiments provide a functional basis 
for the association of the MAPT H1 haplotype with disease.
Tau in parkinsonism
In addition to the mutations in tau linked to FTD, there are a number 
of examples of disorders where tau deposition is linked to a move-
ment disorder phenotype. It is important to note that the clinical 
syndrome of parkinsonism is distinct from PD, which refers to the 
pathologically defined disorder, and also that there are many other 
causes of parkinsonism in addition to those associated with tau 
(Hughes et al., 1992). There are two   historical examples of tau being 
Tau is subject to heavy post-translational modification, and 
hyperphosphorylation, truncation, and glycosylation have all been 
linked to disrupting tau function and promoting tau aggregation. 
This in turn leads to disruption in the microtubule network and 
impaired axonal transport, eventually causing synaptic and neu-
ronal degeneration. It is beyond the scope of this review to discuss 
post-translational modifications to tau and their potential roles 
in neurodegeneration, but a comprehensive overview is given in 
(Iqbal et al., 2009).
Beyond AD, other tauopathies include progressive supranu-
clear palsy (PSP), corticobasal degeneration (CBD), and fronto-
temporal dementia with Parkinsonism linked to chromosome 17 
(FTDP-17; Bird et al., 1999; Gasparini et al., 2007). In addition 
to being characterized by tau deposition, mutations, or common 
variation within MAPT has been linked to these disorders and is 
discussed further below.
The geneTics of MAPT in neurodegeneraTion
The confirmation that tau dysfunction is sufficient to cause neu-
rodegeneration came in 1998 with the discovery of mutations in 
MAPT  that  cause  frontotemporal  dementia  with  parkinsonism 
linked to chromosome 17 (FTDP-17; Hutton et al., 1998; Poorkaj 
et al., 1998). More than 40 tau mutations have been identified to 
date and these can be split into two groups: coding mutations that 
affect the microtubule binding activity of tau and/or its propensity 
to aggregate, and mutations that alter the splicing of exon 10 of 
MAPT (Hasegawa et al., 1998; Jiang et al., 2003). Exon 10 codes for 
the fourth microtubule binding repeat seen in 4R tau isoforms, and 
the majority of splice mutations increase exon 10 inclusion, thereby 
leading to an increase in 4R tau levels. In the adult human CNS the 
ratio of 3R:4R tau is approximately one, which appears to be critical 
for proper neuronal function since mutations that disrupt this ratio 
are sufficient to cause disease. A disruption in tau splicing is also 
seen in the sporadic disorders PSP and CBD, which are characterized 
pathologically by selective deposition of 4R tau isoforms.
As mutations in MAPT cause autosomal dominant disease, 
examining how common variation at the MAPT locus can predis-
pose to sporadic tauopathy has been a major focus of research. The 
genetic architecture of the MAPT locus is complex. The tau gene is 
Table 1 | Genes linked to autosomal forms of Parkinsonism.
PARK  Gene  Inheritance  Phenotype  Pathology
  1  α-Synuclein  Dominant  Complex mix of Parkinsonism and dementia  Lewy bodies
  2  Parkin  Recessive  Juvenile onset Parkinsonism  Nigral cell death, some with Lewy body pathology
  6  PINK1  Recessive  Juvenile onset Parkinsonism  One reported case with Lewy bodies
  7  DJ1  Recessive  Juvenile onset Parkinsonism  No reported pathology
  8  LRRK2  Dominant  Typical Parkinson’s disease  Mixed pathology: Lewy bodies tangles and TDP43
  9  ATP13A2  Recessive  Juvenile onset Parkinsonism  No reported pathology
14  PLA2G6  Recessive  Juvenile onset Parkinsonism dystonia  Lewy bodies
15  FBXO7  Recessive  Juvenile onset Parkinsonism  No reported pathology
  GBA  Dominant  Typical Parkinson’s disease  Lewy bodies
  PANK2  Recessive  Juvenile onset Parkinsonism dystonia  Lewy bodies in NBIA-1 cases
  Tau  Dominant  Frontal temporal dementia with Parkinsonism  Tangles
UCHL1, HTRA2, NR4A2 have all been linked to Parkinson’s disease but are of uncertain provenance. The causative genes for PARK 3, 10, 11, 12, 13, 16 remain to 
be identified.www.frontiersin.org  December 2010  | Volume 1  | Article 150  |  3
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explaining The link beTween MAPT and pd
Although there are many intriguing links between the clinical pres-
entation of Parkinsonism and tau, how relevant these are to PD 
is unclear, and understanding the functional basis for the genetic 
link between tau and pathologically defined PD will be a key area 
of research for the future.
From a genetic perspective, fine mapping of the PD risk haplo-
type has shown that, although the subhaplotype associated with PD 
it is part of the H1 clade, it is a novel haplotype that is associated 
with PD and not the same that is associated with PSP and CBD 
(Tobin et al., 2008). However, increased 4R tau has been detected 
in PD brain suggesting that the common mechanism of increased 
expression underlies the association of MAPT with PD, PSP, and 
CBD (Tobin et al., 2008).
As variation at MAPT influences PD risk, where tangles are not 
consistently found, but has only a moderate influence on AD risk, 
where NFTs are a defining pathological feature (Pittman et al., 2006), 
one could hypothesize that it is some pre-tangle, toxic oligomer species 
that is responsible for tau-mediated neurodegeneration. It is possible 
that NFTs are a marker of damage already done rather than the pri-
mary effector of neurodegeneration. Several lines of evidence have 
recently emerged to support this idea. In AD, tau pathology correlates 
strongly with degree of dementia and the extent of neuronal loss, 
however there is evidence to suggest some neurons die without tan-
gle formation (Gomez-Isla et al., 1997). Additionally, some FTDP-17 
patients with pathogenic mutations in MAPT have relatively few tan-
gles at post-mortem despite widespread neuronal loss (Bird et al., 
1999). Neurodegeneration occurs in a Drosophila model of tauopathy 
without NFT formation, although this was more pronounced in flies 
expressing R406W mutant tau than flies expressing wild-type tau 
(Wittmann et al., 2001). In a transgenic mouse model overexpress-
ing non-mutant, human tau, the presence of tau filaments did not 
correlate with cell death (Andorfer et al., 2005). Inducible transgenic 
mice expressing the P301L FTDP-17 tau mutation continue to accu-
mulate tangles when transgene expression is switched off, despite a 
recovery in cognitive function and stabilization of neuronal numbers, 
providing compelling evidence for the dissociation between NFT for-
mation and neurotoxicity (Santacruz et al., 2005). Further work in 
this model identified several tau multimeric species, which were better 
correlated with neuronal loss and behavioral decline than tau tangles 
(Berger et al., 2007). Equivalent species were isolated from human 
FTD post-mortem brain tissue, suggestive of the existence of a toxic 
tau oligomer (Berger et al., 2007). These data point to the existence of 
a toxic tau species that is yet to be identified. These toxic species may 
not be readily detectable, and would constitute an “invisible assassin,” 
Macavity like character in PD, hitting neurons in the substantia nigra 
but leaving no pawmarks (Eliot, 1939).
inTeracTions beTween mapT, snca, and lrrk2
Further insight into the role of tau as a risk factor in PD can be 
gained from understanding how MAPT interacts with the two other 
major genetic influences on PD risk: SNCA and LRRK2. The known 
interactions between these three proteins are summarized below 
and in Figure 1.
Tau and α-synuclein are both found as insoluble aggregates in 
the tauopathies and synucleinopathies respectively. Several stud-
ies have demonstrated the co-occurrence of tau and α-synuclein 
involved in epidemic Parkinsonism: post-encephalitic Parkinsonism 
and the Parkinsonism/dementia complex (PDC) of Guam (Gibbs 
and Gajdusek, 1972; Wong et al., 1996). The former is Parkinsonism 
found subsequent to cases of von Economos encephalitis, which 
has a temporal if not explicitly causative link to the 1918 Influenza 
epidemic (Casals et al., 1998). The disease was characterized by a 
state of akinetic mutism that proved to be responsive to l-DOPA 
(immortalized by Oliver Sachs in his novel Awakenings). Crucially, 
patients with post-  encephalitic Parkinsonism have extensive tan-
gle pathology in their brains, although the connection between 
this pathology and von Economo’s encephalitis is unclear. Tau is a 
prominent pathological component of the PDC of Guam, part of 
a group of tangle disorders with differing phenotypes that were, 
for a period, a leading cause of death amongst the Chamorros 
people of Guam (Plato et al., 2003). The causative insult of the 
tangle disorders found amongst the Chamorros is unknown, but 
again there is a link between a syndrome involving Parkinsonism 
and tau pathology.
A syndrome with a Parkinsonism component where the causa-
tive insult has been identified is dementia pugilistica, a disorder 
presented by patients who have been the recipient of repeated 
head trauma - most famously exemplified by Muhammed Ali, the 
noted pugilist. Again, this is a disorder with a complex phenotype, 
combining marked cognitive decline with a movement disorder 
component (Roberts et al., 1990; Schmidt et al., 2001). It is also 
notable that head trauma is a significant risk factor for AD, suggest-
ing a causative link between head trauma and tauopathies (Graves 
et al., 1990). The insight that these links yields, however, is limited 
by the fact that we still do not know whether the tau accumulation 
is deleterious or protective to the damaged cells in these cases.
Tau in parkinson’s disease
So far, we have discussed the links between tau and the clinical pres-
entation of parkinsonism, rather than PD, which must be pathologi-
cally defined by the presence of Lewy bodies containing α-synuclein. 
However, the association of tau mutations with the clinical syndrome 
of Parkinsonism in FTDP-17 prompted several groups to analyze 
common variation at the MAPT locus as a risk factor for PD. An asso-
ciation between homozygosity of the H1 haplotype and increased 
PD risk has been described by several groups, although this was 
contradicted by other studies (Farrer et al., 2002; Kwok et al., 2004; 
Skipper et al., 2004; Vandrovcova et al., 2009). However, the recent 
GWAS study identifying MAPT as a risk factor for PD confirm the 
candidate gene association studies using an unbiased experimen-
tal approach (Simon-Sanchez et al., 2009). A separate GWAS in a 
Japanese cohort confirmed the associations of SNCA and LRRK2, but 
failed to identify variation at MAPT as a risk factor for PD (Satake 
et al., 2009). The H2 haplotype is Caucasian in origin and is absent 
from Japanese populations (Evans et al., 2004), suggesting that the 
lack of association in the Japanese cohort is due to population het-
erogeneity at the MAPT locus, rather than lack of reproducibility. 
The lack of tau pathology in idiopathic PD makes the genetic link 
puzzling, especially as MAPT has not been identified as a risk factor 
in GWAS of AD, where NFT pathology is extensive (Lambert et al., 
2009). Why should variation in tau be a risk factor for a disease where 
tau pathology is not consistently observed, but not influence disease 
risk where there is tau deposition is prevalent?Frontiers in Psychiatry  |  Neurodegenerative Diseases    December 2010  | Volume 1  | Article 150  |  4
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with gait impairment, but not other symptoms (Schneider et al., 
2006). This is in contrast to AD, where tangles are found in mainly 
cortical regions and not in the SNPc (Braak and Braak, 1991). 
In PSP and CBD, tangle pathology is most predominant in the 
brainstem, and double immunofluorescence has shown that tau 
and synuclein epitopes colocalize in brainstem Lewy bodies of PD, 
although tau immunoreactivity was only observed in a minority of 
LB (Arima et al., 1999). Finally, post-mortem examination of an 
individual with the rare A53T mutation in α-synuclein revealed 
widespread tau pathology in addition to α-synuclein pathology 
(Duda et al., 2002). The co-occurrence of α-synuclein and tau 
pathology is higher than would be expected from chance alone; 
suggestive of a functional relationship between these two proteins 
and their deposition.
In PD, variation at the SNCA locus has been shown to act syn-
ergistically with variation at MAPT to increase disease risk, i.e., the 
increase in risk when carrying both risk variants is greater than 
the additive risk of carrying each variant in isolation (Goris et al., 
pathologies in the same brain at post-mortem. A high proportion 
of AD cases display synuclein positive Lewy bodies in addition to 
plaques and tangles, and α-synuclein itself was originally isolated 
as the None Amyloid Component of Plaques or NACP (Ueda et al., 
1993). Lewy bodies were detected in the amygdala of 60% of familial 
AD cases as well as 50% of Down’s syndrome cases who had con-
comitant AD (Lippa et al., 1998, 1999). Subsequently, it has been 
shown that the majority of sporadic AD cases also display some 
Lewy body pathology (Hamilton, 2000). A family with early-onset 
dementia characterized pathologically by the widespread appear-
ance of both Lewy Bodies and NFTs, but not amyloid deposits has 
also been described (Clarimon et al., 2009). Additionally, although 
the α-synuclein positive Lewy Body is the pathological hallmark of 
PD, there have been several reports describing the presence of tau 
tangles in PD brain at post-mortem and tangle pathology in PD 
is observed at a higher frequency than in controls (Joachim et al., 
1987; Bancher et al., 1993). One study found tangles in the SNPc 
of 78% of PD patients, and the presence of NFTs was correlated 
FIGuRe 1 | Potential interactions linking tau to cell death in Parkinson’s 
disease patients, showing established links between tau, LRRK2, 
α-synuclein and cellular dysfunction. Tau has been shown to alter the 
aggregation of α-synuclein (1), and has been described as being aggregated 
in mouse models of LRRK2 disease (2). A putative cellular interaction 
between tau, α-synuclein and lrrk2 could impact on a large number of 
cellular processes that all three proteins have been suggested to be involved 
in, including mitochondrial dysfunction (3), impaired translation (4), altered 
autophagy (5), proteasomal dysfunction (6), and altered vesicle  
trafficking (7).www.frontiersin.org  December 2010  | Volume 1  | Article 150  |  5
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As tau is hyperphosphorylated in neurodegeneration, the   obvious 
hypothesis is that tau could be a substrate for LRRK2. However, 
to date, the direct phosphorylation of tau by LRRK2 has not been 
reported. This does not rule out a functional link between the two 
proteins: LRRK2 may influence tau phosphorylation by modulat-
ing the activity of other major tau kinases, such as GSK3beta and 
cdk5. Were this to be the case, it may be that even in cases without 
explicit tau pathology there may be altered phosphorylation of tau. 
It will be interesting to see if levels of tau pathology are enhanced 
in tau and LRRK2 double transgenics. It will also be interesting to 
understand if MAPT risk haplotypes are able to act synergistically 
with LRRK2 variation to influence disease risk.
summary
Recent GWAS have provided compelling evidence that varia-
tion within MAPT is a major risk factor for the development of 
sporadic PD. The lack of tau pathology in sporadic PD makes 
this link puzzling at first glance: however, pathological and func-
tional studies have provided us with some hints as to how MAPT 
may interact with the other PD risk loci, SNCA, and LRRK2, to 
enhance PD risk. In the light of research into Alzheimer’s, where 
a role for tau has been explored for several decades and yet we 
still do not understand the link between the pathology that we 
observe in the post-mortem brain and the underlying process 
that leads to cell death, it is perhaps naive to expect that we 
should immediately comprehend how tau is impacting on the 
disease process in PD. That said, a thorough understanding of 
the links between MAPT, SNCA, and LRRK2 will be crucial to 
understand the etiology of PD, which in turn is critical for the 
development of novel therapies to help those who are afflicted 
by this disorder. The genetic dissection of PD continues apace: 
we now need to develop the tools and approaches to dissect the 
cell biology of this disease, and the highlighting of tau in this 
process can only help us.
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2007). In vitro work has shown that α-synuclein and tau are able 
to influence each other’s polymerization, and diffuse tau pathology 
is observed in transgenic mice expressing the α-synuclein A53T 
mutation (Giasson et al., 2003). Furthermore, transgenic mice 
expressing the A30P α-synuclein mutation display increased tau 
phosphorylation, although interestingly this is not detected in the 
same neurons where synuclein pathology is found (Frasier et al., 
2005). A recent report crossed a triple-transgenic mouse model 
of AD (expressing mutations in APP, PSEN1, and MAPT) with 
a SNCA transgenic, and demonstrated that the resultant mice 
exhibited more rapid cognitive decline than the triple transgenics 
alone (Clinton et al., 2010). As previously observed by Frasier and 
colleagues, tau and α-synuclein pathology did not colocalize in 
the same neurons. Intriguingly, in the synuclein-only transgenics 
the majority of pathology is observed in the brainstem, but in the 
combined transgenics the α-synuclein pathology was predomi-
nantly cortical (Clinton et al., 2010). This suggests an extremely 
tight relationship between tau and α-synuclein levels that is not 
understood at present. Hyperphosphorylation of tau is a common 
feature in all of the tauopathies, and α-synuclein has been shown to 
mediate tau phosphorylation at the pathological epitope S396, and 
increased phosphorylation at this site is observed in PD (Muntane 
et al., 2008; Duka et al., 2009).
Another intriguing genetic link between Parkinsonism and tau 
is provided by one of the other genes highlighted by the GWA 
studies: LRRK2. The autosomal dominant form of PD linked to 
mutations in LRRK2 is characterized by pleomorphic pathology, 
including Lewy bodies, Lewy neurites and, significantly, tau tangles 
(Zimprich et al., 2004). There does not seem to be a direct genotype/
pathology correlation between specific mutations in LRRK2 and 
deposition of a specific type of pathology, indeed patients within the 
same kindred possessing the same mutation can present with dif-
ferent pathologies (Cookson et al., 2008). Evidence for a functional 
link between LRRK2 and tau has been forthcoming from several 
model systems. Tau positive axonal swellings have been observed 
in rat neuronal cultures overexpressing a fragment of LRRK2 and a 
recent mouse model of LRRK2 PD expressing human LRRK2 con-
taining the R1441G mutation displayed extensive tangle   pathology 
(MacLeod et al., 2006).Frontiers in Psychiatry  |  Neurodegenerative Diseases    December 2010  | Volume 1  | Article 150  |  6
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